Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc(TMO)股票分析

$696.490

+24.099 (+3.46%)收盤時

Loading chart…
最高
704.000
開盤
686.130
成交量加權均價
690.65
成交量
3.96M
市值
210.24B
最低
671.470
成交金額
2.74B
企業價值/稅息折舊攤銷前利潤(TTM)
23.21

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.

AI 分析 of Thermo Fisher Scientific Inc (TMO)

買進

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $658.02 and a forward P/E ratio of 24.15, suggesting that the stock is reasonably valued for future growth. The stock has shown a strong year-to-date change of +11.06% and a 1-year change of +25.44%, indicating solid performance. However, the RSI is at 47.83, suggesting it is neither overbought nor oversold, which is favorable for new investors. The main risk is the debt to equity ratio, which stands at 80.76%, indicating a higher level of debt relative to equity, which could impact financial stability if not managed properly.

分析師評級(15)

-5.40% 下跌空間
買進
14 買進
1 持有
0 賣出
目前: 696.49
最低
580.00
平均
658.89
最高
750.00

Morgan Stanley

2026-10-12

目標價

$730

增持

BofA

2026-10-09

目標價

$745

買進

Barclays

2026-10-07

目標價

$750

增持

Deutsche Bank

2026-09-25

目標價

$720

買進

UBS

2026-09-09

目標價

$730

買進

估值指標

Thermo Fisher Scientific Inc(TMO)目前預期本益比為 24.15,5 年平均預期本益比為 23.81。

預期本益比

合理
5 年均值 P/E
23.81
目前P/E
24.15
高估
26.62
低估
20.99

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
20.76
目前EV/EBITDA
23.21
高估
22.69
低估
18.82

預期股價營收比

合理
5 年均值 P/S
4.71
目前P/S
4.94
高估
5.36
低估
4.06

Alphio AI 對 TMO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TMO

$539.08

情境價格

基

基準

基準 · 50%TMO

$476.92

情境價格

悲

悲觀

悲觀 · 25%TMO

$435.11

情境價格

持有 TMO 的大戶

C

Corient Private Wealth LP

+ 持有TMO

+51.28%

3個月報酬率

B

Braidwell LP

+ 持有TMO

+19.42%

3個月報酬率

H

Howard Capital Management, Inc.

+ 持有TMO

+17.25%

3個月報酬率

W

W1M Investment Management Limited

+ 持有TMOGEV

+14.51%

3個月報酬率

T

The Woodbridge Company Limited

+ 持有TMO

+12.68%

3個月報酬率

R

RBC Europe Limited

+ 持有TMO

+11.95%

3個月報酬率

事件時間軸

2026-10-08 (ET)

14:30:00

Nvidia-Backed Lambda Raises $4B, Valuation at $14.5B

2026-10-06 (ET)

06:30:00

Quantum BioPharma Enters Study Start-Up Agreement with Thermo Fisher

2026-09-24 (ET)

06:30:00

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

2026-09-23 (ET)

09:00:00

Thermo Fisher Launches Gibco CHO-K1 Product Portfolio

2026-09-22 (ET)

10:30:00

Trump Proposes $5B Investment in Middle East Energy Infrastructure

資訊

TMO 常見問題 —— 由 Alphio AI 解答

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Thermo Fisher Scientific Inc is a good buy right now, with a current price of $658.02 and a forward P/E ratio of 24.15, suggesting that the stock is reasonably valued for future growth. The stock has shown a strong year-to-date change of +11.06% and a 1-year change of +25.44%, indicating solid performance. However, the RSI is at 47.83, suggesting it is neither overbought nor oversold, which is favorable for new investors. The main risk is the debt to equity ratio, which stands at 80.76%, indicating a higher level of debt relative to equity, which could impact financial stability if not managed properly.

15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易